Vision Loss
Oligonucleotide control of VEGF expression stops choroidal neovascularization
Published in Gene Therapy Weekly, December 16th, 2004
According to recent research from Australia, "ocular neovascularization is the leading cause of blindness in developed countries and the most potent angiogenic factor associated with neovascularization is vascular endothelial growth factor (VEGF). We have previously described a sense oligonucleotide (ODN-1) that possesses anti-human and rat VEGF activity."
"This paper describes the synthesis of lipid-lysine dendrimers and their subsequent ability to delivery ODN-1 to its target and mediate a reduction in VEGF concentration both in vitro and in vivo," said R.J. Marano and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-12-16)
More Articles from Gene Therapy Weekly
- Gene Modification
Peptide-modified alginate surfaces enable re-engineered cells to flourish - Immunology
Local blockade of negative stimulatory molecules augments antitumor cytokines - Metastasis
Reovirus foils the growth of metastatic breast cancer brain lesions - Neurology
Combined gene therapy and cancer immunotherapy attack glioma in murine models - Vaccine Development
Naked sequence-stabilized mRNA vaccine generates immunity to diverse antigens - Addiction Medicine
c-Fos antisense oligodeoxynucleotide counteracts methamphetamine activity - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
